Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity

•High-dose RT upregulated pDCs within the tumor microenvironment.•The administration of intratumoral TLR9 agonist (CMP-001) after stereotactic RT significantly enhanced the anti-tumor immune response both locally and at secondary tumor site.•CMP-001 Post-RT delayed the abscopal tumor growth and exte...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Translational oncology 2021-02, Vol.14 (2), p.100983-100983, Article 100983
Hauptverfasser:	Younes, Ahmed I., Barsoumian, Hampartsoum B., Sezen, Duygu, Verma, Vivek, Patel, Roshal, Wasley, Mark, Hu, Yun, Dunn, Joe D., He, Kewen, Chen, Dawei, Menon, Hari, Masrorpour, Fatemeh, Gu, Meidi, Yang, Liangpeng, Puebla-Osorio, Nahum, Cortez, Maria Angelica, Welsh, James W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abscopal effect Cancer CMP-001 Life Sciences & Biomedicine Oncology Original Research Radiotherapy Science & Technology TLR9 agonist
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!